Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose
A total of 89 adult male Thai patients who had acute, uncomplicated falciparum malaria were treated in a double-blind randomized trial with a single oral dose of two or three tablets, each consisting of 250 mg mefloquine, 500 mg sulfadoxine, and 25 mg pyrimethamine (MSP). The two-tablet regimen prod...
Gespeichert in:
| Veröffentlicht in: | Bulletin of the World Health Organization 1987, Vol.65 (3), p.363-367 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 367 |
|---|---|
| container_issue | 3 |
| container_start_page | 363 |
| container_title | Bulletin of the World Health Organization |
| container_volume | 65 |
| creator | HARINASUTA, T BUNNAG, D VANIJANOND, S CHAROENLARP, P SUNTHARASMAI, P CHITAMAS, S SHETH, U. K WERNSDORFER, W. H |
| description | A total of 89 adult male Thai patients who had acute, uncomplicated falciparum malaria were treated in a double-blind randomized trial with a single oral dose of two or three tablets, each consisting of 250 mg mefloquine, 500 mg sulfadoxine, and 25 mg pyrimethamine (MSP). The two-tablet regimen produced a cure rate (S response) of 93%, the three-tablet regimen a cure rate of 98%. The mean duration of parasitaemia for the two- and three-tablet groups was 50 and 29 hours, respectively, while the mean duration of fever was 43 and 40 hours, respectively. Differences between the groups were not statistically significant. Tolerance was good at both dose levels. The main side-effects were abdominal discomfort, nausea, vomiting, dizziness, and diarrhoea, but these were mild, transient, and required no specific treatment. The results of haematological and biochemical investigations and of urinalysis revealed no drug-related changes following administration of MSP. The electrocardiograms of some patients revealed sinus bradycardia or sinus arrythmia, but these conditions were transient, symptomless, and clinically not significant. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2490999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81058738</sourcerecordid><originalsourceid>FETCH-LOGICAL-p290t-abae24e2cbc36f9bd572a76b258910bda83953abac2e636d0a02bcff2d44dd8a3</originalsourceid><addsrcrecordid>eNpVkcFq3DAQhk1pSbdpH6GgQ-mpBlmSvVYOhRDSNJDSS3I2I2mUVZEsR5JD91nyshHJEhJdBs3_zzfMzLtm0_WDaOlAxftmQ6lgrRzG4WPzKed_tD4p6FFzxHnXCS43zcMftD7erW7GHySv3oKJ_58-MBuy7JMLWHYQaoq4mZQdkpIQSsC5kGhJ3oelxADFaWLBa7dAWgMJ4CE5OCFATFyVx1Z5V4GlJj2xMRGDBVPFuvn2iRpiLgStRV3cPdaqjJ-bDxWZ8cshHjc3v86vz363V38vLs9Or9qFSVpaUIBMINNK88FKZfotg-2gWD_KjioDI5c9ry7NcOCDoUCZ0tYyI4QxI_Dj5uczd1lVQKPraAn8tNTZIe2nCG56q8xuN93G-4kJSaWUFfD9AEh1lZjLFFzW6D3MGNc8jR3txy0fq_Hr604vLQ7nqPq3gw5Zg7cJZu3yi20rqKzX5Y_TKJqH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81058738</pqid></control><display><type>article</type><title>Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>HARINASUTA, T ; BUNNAG, D ; VANIJANOND, S ; CHAROENLARP, P ; SUNTHARASMAI, P ; CHITAMAS, S ; SHETH, U. K ; WERNSDORFER, W. H</creator><creatorcontrib>HARINASUTA, T ; BUNNAG, D ; VANIJANOND, S ; CHAROENLARP, P ; SUNTHARASMAI, P ; CHITAMAS, S ; SHETH, U. K ; WERNSDORFER, W. H</creatorcontrib><description>A total of 89 adult male Thai patients who had acute, uncomplicated falciparum malaria were treated in a double-blind randomized trial with a single oral dose of two or three tablets, each consisting of 250 mg mefloquine, 500 mg sulfadoxine, and 25 mg pyrimethamine (MSP). The two-tablet regimen produced a cure rate (S response) of 93%, the three-tablet regimen a cure rate of 98%. The mean duration of parasitaemia for the two- and three-tablet groups was 50 and 29 hours, respectively, while the mean duration of fever was 43 and 40 hours, respectively. Differences between the groups were not statistically significant. Tolerance was good at both dose levels. The main side-effects were abdominal discomfort, nausea, vomiting, dizziness, and diarrhoea, but these were mild, transient, and required no specific treatment. The results of haematological and biochemical investigations and of urinalysis revealed no drug-related changes following administration of MSP. The electrocardiograms of some patients revealed sinus bradycardia or sinus arrythmia, but these conditions were transient, symptomless, and clinically not significant.</description><identifier>ISSN: 0042-9686</identifier><identifier>EISSN: 1564-0604</identifier><identifier>PMID: 3311439</identifier><identifier>CODEN: BWHOA6</identifier><language>eng</language><publisher>Genève: Organisation mondiale de la santé</publisher><subject><![CDATA[Administration, Oral ; Adolescent ; Adult ; Animals ; Antimalarials - administration & dosage ; Antimalarials - therapeutic use ; Biological and medical sciences ; Double-Blind Method ; Drug Combinations - administration & dosage ; Drug Combinations - therapeutic use ; Human protozoal diseases ; Humans ; Infectious diseases ; Malaria ; Malaria - drug therapy ; Male ; Medical sciences ; Mefloquine - analogs & derivatives ; Parasitic diseases ; Plasmodium falciparum ; Protozoal diseases ; Pyrimethamine - administration & dosage ; Pyrimethamine - therapeutic use ; Quinolines - administration & dosage ; Quinolines - therapeutic use ; Random Allocation ; Sulfadoxine - administration & dosage ; Sulfadoxine - therapeutic use ; Sulfanilamides - therapeutic use ; Thailand ; Tropical medicine]]></subject><ispartof>Bulletin of the World Health Organization, 1987, Vol.65 (3), p.363-367</ispartof><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2490999/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2490999/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7409564$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3311439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HARINASUTA, T</creatorcontrib><creatorcontrib>BUNNAG, D</creatorcontrib><creatorcontrib>VANIJANOND, S</creatorcontrib><creatorcontrib>CHAROENLARP, P</creatorcontrib><creatorcontrib>SUNTHARASMAI, P</creatorcontrib><creatorcontrib>CHITAMAS, S</creatorcontrib><creatorcontrib>SHETH, U. K</creatorcontrib><creatorcontrib>WERNSDORFER, W. H</creatorcontrib><title>Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose</title><title>Bulletin of the World Health Organization</title><addtitle>Bull World Health Organ</addtitle><description>A total of 89 adult male Thai patients who had acute, uncomplicated falciparum malaria were treated in a double-blind randomized trial with a single oral dose of two or three tablets, each consisting of 250 mg mefloquine, 500 mg sulfadoxine, and 25 mg pyrimethamine (MSP). The two-tablet regimen produced a cure rate (S response) of 93%, the three-tablet regimen a cure rate of 98%. The mean duration of parasitaemia for the two- and three-tablet groups was 50 and 29 hours, respectively, while the mean duration of fever was 43 and 40 hours, respectively. Differences between the groups were not statistically significant. Tolerance was good at both dose levels. The main side-effects were abdominal discomfort, nausea, vomiting, dizziness, and diarrhoea, but these were mild, transient, and required no specific treatment. The results of haematological and biochemical investigations and of urinalysis revealed no drug-related changes following administration of MSP. The electrocardiograms of some patients revealed sinus bradycardia or sinus arrythmia, but these conditions were transient, symptomless, and clinically not significant.</description><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Animals</subject><subject>Antimalarials - administration & dosage</subject><subject>Antimalarials - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Drug Combinations - administration & dosage</subject><subject>Drug Combinations - therapeutic use</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Malaria</subject><subject>Malaria - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mefloquine - analogs & derivatives</subject><subject>Parasitic diseases</subject><subject>Plasmodium falciparum</subject><subject>Protozoal diseases</subject><subject>Pyrimethamine - administration & dosage</subject><subject>Pyrimethamine - therapeutic use</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - therapeutic use</subject><subject>Random Allocation</subject><subject>Sulfadoxine - administration & dosage</subject><subject>Sulfadoxine - therapeutic use</subject><subject>Sulfanilamides - therapeutic use</subject><subject>Thailand</subject><subject>Tropical medicine</subject><issn>0042-9686</issn><issn>1564-0604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkcFq3DAQhk1pSbdpH6GgQ-mpBlmSvVYOhRDSNJDSS3I2I2mUVZEsR5JD91nyshHJEhJdBs3_zzfMzLtm0_WDaOlAxftmQ6lgrRzG4WPzKed_tD4p6FFzxHnXCS43zcMftD7erW7GHySv3oKJ_58-MBuy7JMLWHYQaoq4mZQdkpIQSsC5kGhJ3oelxADFaWLBa7dAWgMJ4CE5OCFATFyVx1Z5V4GlJj2xMRGDBVPFuvn2iRpiLgStRV3cPdaqjJ-bDxWZ8cshHjc3v86vz363V38vLs9Or9qFSVpaUIBMINNK88FKZfotg-2gWD_KjioDI5c9ry7NcOCDoUCZ0tYyI4QxI_Dj5uczd1lVQKPraAn8tNTZIe2nCG56q8xuN93G-4kJSaWUFfD9AEh1lZjLFFzW6D3MGNc8jR3txy0fq_Hr604vLQ7nqPq3gw5Zg7cJZu3yi20rqKzX5Y_TKJqH</recordid><startdate>1987</startdate><enddate>1987</enddate><creator>HARINASUTA, T</creator><creator>BUNNAG, D</creator><creator>VANIJANOND, S</creator><creator>CHAROENLARP, P</creator><creator>SUNTHARASMAI, P</creator><creator>CHITAMAS, S</creator><creator>SHETH, U. K</creator><creator>WERNSDORFER, W. H</creator><general>Organisation mondiale de la santé</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>1987</creationdate><title>Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose</title><author>HARINASUTA, T ; BUNNAG, D ; VANIJANOND, S ; CHAROENLARP, P ; SUNTHARASMAI, P ; CHITAMAS, S ; SHETH, U. K ; WERNSDORFER, W. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p290t-abae24e2cbc36f9bd572a76b258910bda83953abac2e636d0a02bcff2d44dd8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Animals</topic><topic>Antimalarials - administration & dosage</topic><topic>Antimalarials - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Drug Combinations - administration & dosage</topic><topic>Drug Combinations - therapeutic use</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Malaria</topic><topic>Malaria - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mefloquine - analogs & derivatives</topic><topic>Parasitic diseases</topic><topic>Plasmodium falciparum</topic><topic>Protozoal diseases</topic><topic>Pyrimethamine - administration & dosage</topic><topic>Pyrimethamine - therapeutic use</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - therapeutic use</topic><topic>Random Allocation</topic><topic>Sulfadoxine - administration & dosage</topic><topic>Sulfadoxine - therapeutic use</topic><topic>Sulfanilamides - therapeutic use</topic><topic>Thailand</topic><topic>Tropical medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HARINASUTA, T</creatorcontrib><creatorcontrib>BUNNAG, D</creatorcontrib><creatorcontrib>VANIJANOND, S</creatorcontrib><creatorcontrib>CHAROENLARP, P</creatorcontrib><creatorcontrib>SUNTHARASMAI, P</creatorcontrib><creatorcontrib>CHITAMAS, S</creatorcontrib><creatorcontrib>SHETH, U. K</creatorcontrib><creatorcontrib>WERNSDORFER, W. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bulletin of the World Health Organization</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HARINASUTA, T</au><au>BUNNAG, D</au><au>VANIJANOND, S</au><au>CHAROENLARP, P</au><au>SUNTHARASMAI, P</au><au>CHITAMAS, S</au><au>SHETH, U. K</au><au>WERNSDORFER, W. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose</atitle><jtitle>Bulletin of the World Health Organization</jtitle><addtitle>Bull World Health Organ</addtitle><date>1987</date><risdate>1987</risdate><volume>65</volume><issue>3</issue><spage>363</spage><epage>367</epage><pages>363-367</pages><issn>0042-9686</issn><eissn>1564-0604</eissn><coden>BWHOA6</coden><abstract>A total of 89 adult male Thai patients who had acute, uncomplicated falciparum malaria were treated in a double-blind randomized trial with a single oral dose of two or three tablets, each consisting of 250 mg mefloquine, 500 mg sulfadoxine, and 25 mg pyrimethamine (MSP). The two-tablet regimen produced a cure rate (S response) of 93%, the three-tablet regimen a cure rate of 98%. The mean duration of parasitaemia for the two- and three-tablet groups was 50 and 29 hours, respectively, while the mean duration of fever was 43 and 40 hours, respectively. Differences between the groups were not statistically significant. Tolerance was good at both dose levels. The main side-effects were abdominal discomfort, nausea, vomiting, dizziness, and diarrhoea, but these were mild, transient, and required no specific treatment. The results of haematological and biochemical investigations and of urinalysis revealed no drug-related changes following administration of MSP. The electrocardiograms of some patients revealed sinus bradycardia or sinus arrythmia, but these conditions were transient, symptomless, and clinically not significant.</abstract><cop>Genève</cop><pub>Organisation mondiale de la santé</pub><pmid>3311439</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-9686 |
| ispartof | Bulletin of the World Health Organization, 1987, Vol.65 (3), p.363-367 |
| issn | 0042-9686 1564-0604 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2490999 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Administration, Oral Adolescent Adult Animals Antimalarials - administration & dosage Antimalarials - therapeutic use Biological and medical sciences Double-Blind Method Drug Combinations - administration & dosage Drug Combinations - therapeutic use Human protozoal diseases Humans Infectious diseases Malaria Malaria - drug therapy Male Medical sciences Mefloquine - analogs & derivatives Parasitic diseases Plasmodium falciparum Protozoal diseases Pyrimethamine - administration & dosage Pyrimethamine - therapeutic use Quinolines - administration & dosage Quinolines - therapeutic use Random Allocation Sulfadoxine - administration & dosage Sulfadoxine - therapeutic use Sulfanilamides - therapeutic use Thailand Tropical medicine |
| title | Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T15%3A06%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mefloquine,%20sulfadoxine,%20and%20pyrimethamine%20in%20the%20treatment%20of%20symptomatic%20falciparum%20malaria:%20a%20double-blind%20trial%20for%20determining%20the%20most%20effective%20dose&rft.jtitle=Bulletin%20of%20the%20World%20Health%20Organization&rft.au=HARINASUTA,%20T&rft.date=1987&rft.volume=65&rft.issue=3&rft.spage=363&rft.epage=367&rft.pages=363-367&rft.issn=0042-9686&rft.eissn=1564-0604&rft.coden=BWHOA6&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E81058738%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=81058738&rft_id=info:pmid/3311439&rfr_iscdi=true |